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Abstract
Purpose In Europe, intravenous fosfomycin (IV) is used particularly in difficult-to-treat or complex infections, caused by 
both Gram-positive and Gram-negative pathogens including multidrug-resistant strains. Here, we investigated the efficacy 
and safety of intravenous fosfomycin under real-life conditions.
Methods Prospective, multi-center, and non-interventional study in patients with bacterial infections from 20 intensive care 
units (ICU) in Germany and Austria (NCT01173575).
Results Overall, 209 patients were included (77 females, 132 males, mean age: 59 ± 16 years), 194 of which were treated in 
intensive care (APACHE II score at the beginning of fosfomycin therapy: 23 ± 8). Main indications (± bacteremia or sepsis) 
were infections of the CNS (21.5%), community- (CAP) and hospital-acquired pneumonia (HAP)/ventilator-associated 
pneumonia (VAP, 15.3%), bone and joint infections (BJI, 11%), abdominal infections (11%), and bacteremia (10.5%). 
Most frequently identified pathogens were S. aureus (22.3%), S. epidermidis (14.2%), Enterococcus spp. (10.8%), E. coli 
(12.3%) and Klebsiella spp. (7.7%). At least one multidrug-resistant (MDR) pathogen was isolated from 51 patients (24.4%). 
Fosfomycin was administered with an average daily dose of 13.7 ± 3.5 g over 12.4 ± 8.6 days, almost exclusively (99%) in 
combination with other antibiotics. The overall clinical success was favorable in 81.3% (148/182) of cases, and in 84.8% 
(39/46) of patients with ≥ 1 MDR pathogen. Noteworthy, 16.3% (34/209) of patients developed at least one, in the majority 
of cases non-serious, adverse drug reaction during fosfomycin therapy.
Conclusion Our data suggest that IV fosfomycin is an effective and safe combination partner for the treatment of a broad 
spectrum of severe bacterial infections in critically ill patients.
Keywords Intravenous fosfomycin · Non-interventional study · Intensive care · Gram-positive · Gram-negative · Multidrug 
resistance
Introduction
Fosfomycin is a bactericidal broad-spectrum antibiotic 
active against a variety of Gram-positive (GP) and Gram-
negative (GN) pathogens including ‘problem bacteria’ such 
as carbapenemase- or extended-spectrum beta-lactamase 
(ESBL)-producing Enterobacteriaceae, methicillin-resist-
ant Staphylococcus aureus (MRSA), glycopeptide-resistant 
enterococci and multidrug-resistant (MDR) Pseudomonas 
aeruginosa [1–5], supported by synergistic effects with 
many other antibiotics [6, 8]. Due to the unique chemical 
structure, cross-resistance and -allergies with other antibiot-
ics have not been reported so far [7]. Fosfomycin exhibits 
advantageous pharmacokinetic properties making it par-
ticularly useful for complicated deep-seated, even biofilm-
associated infections such as respiratory tract, bone or cen-
tral nervous system (CNS) infections [7, 9–14]. Fosfomycin 
can be used without any age limitations. However, due to 
the high sodium load (1 g fosfomycin contains 14 mmol 
(320 mg) sodium), electrolyte imbalances such as hyperna-
tremia or hypokalemia might occur [6, 15].
Fosfomycin was included in the WHO list of essen-
tial medicines for treatment of adults and children within 
the RESERVE group of antibacterial medicines [16, 17]. 
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Prospective, randomized, controlled clinical trials with fos-
fomycin in mono- and combination therapy, though having 
been initiated recently, are still ongoing. Currently, data on 
the efficacy and safety of intravenous (IV) fosfomycin in 
the daily clinical practice are still limited. In addition, fos-
fomycin is used for indications for which no randomized 
controlled trials would likely to be feasible due to constraints 
regarding time and study design.
Here, we present real-life efficacy and safety data on the 
current clinical use of IV fosfomycin in two countries with 
longstanding experience from the largest prospective non-
interventional study conducted to date.
Patients and methods
Description of the study
The present trial is a prospective, open-label, multi-center, 
and non-interventional study (NIS-FOM; NCT01173575). 
According to international recommendations, fosfomycin 
was administered or prescribed based on license approval 
[18]. The unbiased assignment of a patient to a specific 
therapeutic strategy was made in best knowledge by inves-
tigators in advance, and always met current clinical practice 
and standards.
Of 25 centers which agreed to participate, 20 recruited 
patients between June 2010 and June 2016. Database lock 
was in November 2016 after finalization of documentation 
of the last patient including queries in October 2016.
The NIS-FOM study including ICF was approved by the 
ethics committees of participating study centers. Before 
approval by each study center, the study was approved on 
20th August 2010 (Bonn, referral no. 140/10) by the ethics 
committee at the “coordinating” investigator’s study center 
who signed the study protocol (Medical Department of the 
University of Bonn). Before inclusion into the study written 
informed consent was obtained from every single patient or 
patient’s parent(s)/legal guardian(s).
It was the responsibility of the study sites and/or health 
insurances to bear or reimburse all costs of antimicrobial 
therapy including IV fosfomycin within the scope of the 
study, as this reflected antibiotic standard of care within the 
study center. There was no funding by the manufacturer with 
regards to study medication. Despite this, every study center 
received an appropriate and defined expense allowance for 
each patient documentation including queries.
Patient enrollment and populations
All consecutive patients of the participating study centers 
who received treatment with IV fosfomycin were enrolled, 
provided that informed consent was obtained. Treatment 
with fosfomycin and the course of infection were followed 
in terms of clinical and microbiological treatment success 
and safety until discharge or death, if possible. Any indica-
tion for fosfomycin treatment was sufficient for inclusion 
of patients. Patient enrollment was delayed due to an IV 
fosfomycin shortage from 2011 to 2013.
All documented patients who received at least one dose of 
intravenous fosfomycin comprise the intention-to-treat (ITT) 
population or ‘safety population’. All documented patients 
who received at least one dose of IV fosfomycin and had 
an evaluable clinical efficacy endpoint form the clinical per 
protocol (cPP) population or ‘clinical effectiveness popula-
tion’. All documented patients who received at least one dose 
of IV fosfomycin and had an evaluable microbiological effi-
cacy endpoint form the microbiological per protocol (mPP) 
population or ‘microbiological effectiveness population’.
Recorded data
An internet-based electronic case report form (eCRF) was 
used to gather data on the clinical and microbiological effi-
cacy of fosfomycin after intravenous therapy. All data were 
(pseudo)-anonymized by the investigators at each study 
center and verified by double-entry procedure.
Recorded data included demographic characteristics, 
admission and definite diagnosis, height, weight, body 
mass index (BMI), medical history and treatment indica-
tion, intensive care, fosfomycin dose, duration and dosing 
schedule, pathogens isolated, susceptibility pattern and 
MDR status, diagnostic methods with respect to infection, 
relevant concomitant diseases and risk factors, laboratory 
parameters, APACHE score at baseline and after fosfomy-
cin treatment, body temperature, antimicrobial pretreatment, 
concomitant antimicrobial agents and duration of hospital 
stay.
Microbiology and culture procedures
All microbiological, culture and susceptibility testing proce-
dures were performed according to the local standard operat-
ing procedures of the respective centers.
Definitions and outcomes
Overall clinical success was defined either as clinical cure or 
clinical improvement. Microbiological success was defined 
as eradication of the underlying pathogen.
Clinical cure was defined as resolution of signs and symp-
toms of infection and/or no additional antibiotic therapy nec-
essary. Clinical improvement was defined as improvement 
of signs and symptoms of infection and/or improvement of 
signs and symptoms of infection and administration of addi-
tional antibiotic therapy.
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Criteria for evaluation included efficacy and safety 
measurements. The primary efficacy endpoint was clini-
cal success. Secondary efficacy endpoints included the 
number of patients with cure of infection, improvement 
of infection, unaltered infection, clinical treatment fail-
ure, pathogen eradicated, and microbiological treatment 
failure.
Clinical efficacy outcome variables were clinical/
microbiological efficacy on day 7 ± 1, day 14 ± 1 and at 
discharge. The primary efficacy outcome variable was 
the efficacy at the first assessment day after end of fos-
fomycin treatment. For cases with missing data, the last 
observation was carried forward.
For safety analysis the number of patients with adverse 
events (AEs), adverse drug reactions (ADRs), serious 
adverse events (SAEs), number of deaths, and tolerabil-
ity were recorded.
The term ‘difficult-to-treat’ infection was used accord-
ing to common definitions in the literature for deep-seated 
infections associated with a poor penetration of antibiot-
ics (e.g., CNS infections, bone and joint infections or for-
eign body associated infections with or without abscess 
involvement), infections where previous antibiotic (stand-
ard) treatment has already failed or infections in patients 
with high risk of complications (co-morbidities, co-med-
ication, and drug allergies) [19, 20].
Statistical analysis
The statistical analysis was performed using the statistical 
software SPSS v. 23.0 (IBM). Continuous variables were 
expressed by mean ± standard deviation or median and 
interquartile range (IQR) as appropriate.
Results
Overall, 209 patients were included (ITT population), for 
which an evaluable clinical endpoint was attained in 182 
cases (cPP population) and an evaluable microbiological 
endpoint in 90 cases (mPP population). In detail, 172 of the 
patients were enrolled in 19 German study centers and 37 in 
one Austrian study center.
Demographic and baseline characteristic
Patients enrolled were predominantly critically ill, with an 
APACHE II (III) score at the beginning of fosfomycin treat-
ment of 23 ± 8 (data from 71 patients). Virtually all patients 
were treated in intensive care (92.8%), while 65.1% (n = 136) 
had pre-existing risk factors for bacterial infections such as 
diabetes mellitus, smoking, immunosuppression/corticoster-
oids, chronic renal insufficiency, liver cirrhosis and intensive 
antibiotic pretreatment within the last month. Most patients 
(71.8%) had received a targeted therapy and 73.2% (n = 153) 
a prior therapy with other antibiotics. The patients’ demo-
graphic and clinical characteristics are presented in Table 1.
Description of the infection and microbiological 
data
Main indications for fosfomycin administration were infec-
tions of the CNS (n = 45, 21.5%), pneumonia including CAP, 
HAP and VAP (n = 32, 15.3%), BJI (n = 23, 11%), abdominal 
infection (SAI, n = 23, 11%), endocarditis (all with sepsis or 
bacteremia, n = 9, 4.3%), complicated urinary tract infec-
tion (cUTI, n = 8, 3.8%) and sepsis or bacteremia (n = 22, 
10.5%), half of them just with signs of infection or bactere-
mia but unknown focus. Multiple infections with more than 
one focus or infections that could not be assigned to one of 
the other categories were found in 33 (15.8%) patients (see 
Fig. 1). Overall, 57 (27.3%) patients developed a clinically 
and microbiologically confirmed sepsis or bacteremia during 
Table 1  Description of the 
demographic and baseline 
characteristics
Data are mean ± standard deviation; * 192 patients; # APACHE II (in 71 patients); ** APACHE III (in 19 
patients)
Characteristic n %
Age (years) 59.1 ± 16.4
Gender (m/w) 132/77 63.2/36.8
BMI (kg/m2) 28.3 ± 6.9*
Intensive care patients 194 92.8
Patients with risk factors for bacterial infections 136 65.1
APACHE II (III) score at begin of fosfomycin therapy 23 ± 8#/104 ± 18**
Patients with antibiotic pretreatment 153 73.2
Patients with identified pathogen before start of fosfomycin 
therapy
150 71.8
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the course of infection. One or at least two organ systems 
(± bacteremia) were affected in 161 (77%) and 37 (17.7%) 
patients, respectively.
Many infections were polybacterial (n = 77, 36.8%), 
whereas 60 patients (28.7%) had infections by only one 
pathogen. In 72 (34.4%) patients, no bacteria or other defi-
nite causality for infection could be identified. The majority 
of pathogens was GP (141 isolates, 54.2%). GN pathogens 
were found in 110 isolates (42.3%) and other anaerobes in 
9 isolates (3.5%). Fungi were found in 31 patients (14.8%). 
The full microbiological spectrum of the 260 isolates is 
shown in Table 2.
In total, 51 patients (24.4%) presented infections due to 
at least one MDR pathogen. ESBL-producing bacteria were 
found in four isolates. The resistance pattern of S. aureus 
was not consistently reported for all isolates. In detail, only 
28 monobacterial S. aureus infections were assessable, 75% 
(21/28) caused by methicillin-sensitive strains (MSSA), while 
MRSA was isolated in 25% (7/28) of cases.
Mode and duration of therapy
The average daily fosfomycin dose was 13.7 ± 3.5 g, generally 
split into 2–4 single doses. Total daily fosfomycin doses ranged 
between 3 and 24 g, as indicated. The majority of patients 
(n = 166) received 15 g per day or less (standard dose group), 
and 41 patients received more than 15 g per day (high-dose 
group). The average fosfomycin dose for patients with infec-
tions due to GP pathogens was 13.2 ± 7.0 g/d and 13.6 ± 6.9  
g/day for infections due to GN pathogens. For two patients, the 
fosfomycin dose was not reported. The mean treatment dura-
tion was 12.4 ± 8.6 days, strongly depending on the indication: 
average treatment duration was 20 days in BJI and sepsis, and 
6 days in cUTI.
Fifty-six patients (26.8%) received fosfomycin as first-line 
therapy, particularly for infections of a single organ system 
(49/161, 30.4%). For infections of two or more organ systems, 
fosfomycin was used less frequently as the first-line treat-
ment (6/32, 6.2%). As a first-line therapy, fosfomycin was 
employed most frequently in patients with CNS infections 
(25/45, 55.5%), followed by cUTI (4/8, 50%), endocarditis 
(2/9, 22.2%), abdominal infections (5/23, 21.7%), bacterial 
pneumonia (6/32, 18%), BJI (4/23, 17.4%), and sepsis or bac-
teremia with unknown entry (1/11, 9.1%). In patients with skin 
and soft tissue infections (SSTI), fosfomycin was used at least 
as second-line option.
Fosfomycin was nearly exclusively used in combination 
therapy (207 patients, 99%) and predominantly combined with 
a beta-lactam, glycopeptide, metronidazole and/or a quinolone 
(Table 3). Most patients were treated with one (80 patients), 
two (72 patients) or three (30 patients) combination partners. 
More than three concomitant antibiotics were administered 
in 25 patients.
Combination regimens of the three most frequently reported 
indications are shown in Table 4.
A carbapenem was the preferred combination partner for 
fosfomycin, except in patients with CNS infections. Here, fos-
fomycin was predominantly combined with a third- or fourth-
generation cephalosporin.
Clinical/microbiological efficacy and emergence 
of resistance
Overall clinical success was 81.3% (Table 5) and micro-
biological success was 70% (Table 6). No emergence of 
CNS infection* 






sepsis, and signs 
of infection  
10.5% 

















Fig. 1  Types of infection (n = 209); *± bacteremia or sepsis; **mul-
tiple infections or infections that could not be assigned to one of the 
other categories
Table 2  Microbiological spectrum (data from mono- and polybacte-
rial infections)
Pathogen n (%)
Staphylococcus aureus 58 (22.3)
Staphylococcus epidermidis/coagulase-negative  
staphylococci
37 (14.2)
Escherichia coli 32 (12.3)
Enterococcus spp. 28 (10.8)
Klebsiella spp. 20 (7.7)
Enterobacter/Citrobacter spp. 17 (6.5)
Pseudomonas aeruginosa 12 (4.6)
Streptococcus spp. 9 (3.5)
Proteus spp. 6 (2.3)
Serratia spp. 4 (1.5)
Other Gram-negative pathogens 19 (7.3)
Other Gram-positive pathogens 9 (3.6)
Anaerobes 9 (3.5)
831Current clinical use of intravenous fosfomycin in ICU patients in two European countries 
1 3
resistance against fosfomycin was observed during fosfo-
mycin treatment.
In patients with infections of a single organ system, clini-
cal success was achieved in 82.1% (115/140) of patients. 
With infections of two or more organ systems, clinical suc-
cess was just slightly lower (75%, 24/32). The highest clini-
cal success rate of 90% (9/10) was found in patients with 
signs of infection or bacteremia, but unknown focus. Eradi-
cation could be achieved in all patients with BJI, SSTI and 
endocarditis. The clinical and microbiological success per 
indication is shown in Table 7.
Clinical success rates in the standard and high-dose 
groups were virtually identical (81.1% vs. 81.3% (cPP)). 
In two patients with clinical cure, fosfomycin dosage was 
unknown.
In cases involving MDR pathogens, clinical and micro-
biological success rates were 84.8% (39/46 (cPP)) and 81.5% 
(22/27 (mPP)), respectively. Clinical and microbiological 
success rates in infections due to MRSA were 100% (6/6 
(cPP)) and 66.7% (4/6 (mPP)), in MSSA 76.2% (16/21 
(cPP)) and 100% (9/9 (mPP)), respectively.
If fosfomycin was combined with either a carbapenem, 
cephalosporin or a penicillin, pooled clinical success rates 
were 80.8%, 87.5%, and 85.7%, respectively (Table 8).
Table 3  Fosfomycin combination partners with number of patients 
per class (n = 209)





3rd- or 4th-generation cephalosporin 58 27.8














Table 4  Fosfomycin combination partners in subgroups of patients 
with bacterial pneumonia, abdominal infection and CNS infection (all 
without sepsis or bacteremia)
HAP hospital-acquired pneumonia; CAP community-acquired pneu-
monia; VAP ventilator-associated pneumonia; BLI beta-lactamase 
inhibitor; CNS central nervous system
Combination partner Number 
of patients 
(%)
Patients with bacterial pneumonia (CAP, HAP or VAP) 25 (100)
 Carbapenem 15 (60.0)
 Glycopeptide 7 (28.0)
 3rd- or 4th-generation cephalosporin 6 (24.0)
 Colistin 5 (20.0)
 Quinolone 4 (16.0)
Patients with abdominal infection 22 (100)
 Carbapenem 18 (81.8)
 3rd- or 4th-generation cephalosporin 4 (18.2)
 Glycopeptide, penicillin + BLI or metronidazole 3 (13.6)
Patients with CNS infection 44 (100)




Table 5  Clinical efficacy endpoints (n = 209)
cPP clinical per protocol population
*According to physicians’ assessment, no definite classification. Last 
documented observation carried forward independently of previous 
assessments at earlier time points (e.g., day 7 or 14)
Efficacy endpoint n % % (cPP)
Cure 63 30.1 34.6
Improvement 85 40.7 46.7
Failure 19 9.1 10.4
Unchanged 15 7.2 8.3
Not reported 3 1.4
Not assessable* 24 11.5
Table 6  Microbiological efficacy endpoints (n = 209)
mPP microbiological per protocol population
Efficacy endpoint n % % (mPP)




Not reported 3 1.5
Not determined 47 22.5
Not assessable 69 33.0
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Safety
In total, 70 adverse events (AEs) were reported in 63 patients 
(30.1%). In seven patients, two AEs were reported, but no 
patient experienced more than two AEs. Thirty-nine AEs 
were considered being related to the study drug (adverse 
drug reactions, ADR), three of which were assessed as seri-
ous. One of these three patients developed a multiple organ 
failure, another an acute respiratory insufficiency in pneu-
monia and a terminal cystic fibrosis, both with fatal outcome 
and both considered being unlikely related to fosfomycin. 
The third serious ADR was a severe hypokalemia that did 
not lead to discontinuation of fosfomycin treatment, how-
ever. A summary of the safety analysis is shown in Table 9.
Most common adverse events were hypernatremia (n = 31, 
14.8%) and hypokalemia (n = 13, 6.2%). A causal relation-
ship to fosfomycin was suspected in 22 (10.5%) patients 
with hypernatremia and five (2.4%) with hypokalemia. Of 
Table 7  Clinical and 
microbiological success per 
indication
MDR multidrug-resistant, GP/GN Gram-positive/-negative; MS-/MRSA methicillin-susceptible/methicillin-
resistant S. aureus
*± Sepsis or bacteremia, **all with sepsis or bacteremia, #microbiologically confirmed (= targeted therapy)
Indication Clinical success (cPP) Microbiological 
success (eradica-
tion, mPP)
n % n %
All patients 148/182 81.3 63/90 70.0
CNS infections* 33/37 89.1 9/11 81.8
Pneumonia (CAP, HAP, VAP)* 23/27 85.2 7/13 53.8
Bacteremia, sepsis, and signs of infection 17/20 85.0 7/10 70.0
 Bacteremia with unknown focus and signs of infection 9/10 90 4/5 80.0
Bone and join infections* 18/21 85.7 13/13 100.0
Abdominal infections* 16/22 72.7 3/10 30.0
Skin and soft tissue infections* 10/12 83.3 8/8 100.0
Endocarditis** 6/9 66.7 4/4 100.0
Complicated urinary tract infections* 6/7 85.7 5/6 83.3
Infection due to MDR pathogens 39/46 84.8 22/27 81.5
Infection due to GP  pathogens# 49/65 75.4 23/33 69.7
Infection due to GN  pathogens# 20/25 80.0 10/13 76.9
Infection due to GP and GN pathogens (polybacterial)# 35/37 94.6 23/21 90.5
Infection due to MSSA 16/21 76.2 9/9 100
Infection due to MRSA 6/6 100 4/6 66.7
Infection without identified pathogens 44/55 80.0
Table 8  Clinical success of fosfomycin in combination therapy (com-
binations of fosfomycin with one other concomitant antibiotic only)
n no. of patients; ITT intention-to-treat population, cPP clinical per 
protocol population





Carbapenems 30 Meropenem (27) 80.8% (21/26)
Imipenem (3)












Table 9  Summary of safety analysis (adverse events, adverse drug 
reactions* and death)
*Considered as being related to fosfomycin
AE adverse event, ADR adverse drug reaction
Classification n n(patients) % (ITT)
AE(total) 70 63 30.1
 Non-serious ADR* 36 31 14.8
 Serious ADR* 3 3 1.4
Death 15 15 7.2
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note, one and six patients, respectively, had hypokalemia 
or hypernatremia prior to fosfomycin treatment. Only four 
patients developed hypokalemia concomitantly with hyper-
natremia. In one patient, occurrence of an AE was formally 
documented, but not further specified. An overview of all 
AEs is shown in Table 10.
In eight patients, fosfomycin treatment was discontinued 
due to an adverse event, with hypernatremia being the cause 
in six of these cases. In the remaining two cases, therapy 
was stopped either due to an allergic reaction or pyrexia 
and nausea.
Discussion
To date, this study is the largest non-interventional study 
focusing on the use of intravenous fosfomycin in the daily 
clinical practice. In total, 209 critically ill patients were 
enrolled, presenting with severe, life-threatening infections. 
Severity of illness of our patients was higher as of those 
reported in a previous study [39].
In our study, we found a broad use of IV fosfomycin 
against both GP and GN pathogens with a higher propor-
tion of Gram-positives (54.2%). The widespread spectrum 
of indications ranging from infections predominantly caused 
by Gram-negatives such as cUTI to others most often asso-
ciated with GP pathogens such as CNS infections, BJI or 
endocarditis, indicate that fosfomycin has been used across 
different sites of infection. High in vitro activity against 
several ‘problem bacteria’, in particular S. aureus and S. 
epidermidis, is clinically reflected by the large number of 
staphylococcal infections (36.5%) treated in NIS-FOM [21, 
22]. Despite several alternative therapeutic options, fosfo-
mycin was mostly used in MSSA infections [23, 24]. This 
might suggest that severe S. aureus infections with deep 
focus might represent entities not yet adequately covered by 
standard therapy [25].
In contrast to studies solely reporting on the use of IV 
fosfomycin as a last-resort option in infections due to MDR 
GN pathogens such as carbapenemase-producing Enterobac-
teriaceae or ESBL-producers [26, 33, 38, 39], data from this 
two-country study suggest that only in 24% of all patients 
the indication for fosfomycin use was an infection caused 
by MDR pathogens. More often it was used as a combina-
tion partner against other difficult-to-treat infections with 
limited therapeutic options or where the first-line treatment 
had already failed. In difficult-to-treat infections, even in 
those with biofilm involvement, IV fosfomycin has become 
a valuable combination partner supported by its advanta-
geous pharmacokinetic properties [26–28, 30]. Its chemical 
properties allow fosfomycin to penetrate deep into tissues, 
even into bones and the CNS, which might explain the pre-
ferred use in CNS infections (22.3%) such as brain abscesses 
or bacterial meningitis, BJI (14.2%), or sepsis (10.5%) [11, 
13, 29].
The broad spectrum of combination partners might be 
due to synergistic or additive effects of fosfomycin with 
many other classes of antibiotics that could be explained 
by inhibiting the bacterial cell wall synthesis at an earlier 
stage than other antibiotics (e.g., beta-lactams) [2]. Interest-
ingly, our data indicate that fosfomycin was not used as a 
carbapenem-sparing treatment option, evermore discussed in 
the literature [31, 32]. Instead, in infections like nosocomial 
pneumonia (HAP, VAP) or abdominal infection (Table 4) 
fosfomycin was most often combined with a carbapenem. 
This combination is supported by synergistic effects and has 
recently been recommended, especially if MDR GN patho-
gens are involved [26, 33–36].
Although IV fosfomycin is generally considered a sec-
ond-line treatment option, it was used in first-line therapy in 
more than a quarter of patients. Given its ability to rapidly 
cross the blood/brain barrier, fosfomycin may be regarded 
as a useful combination partner for treatment of CNS infec-
tions, e.g., when combined with a third- or fourth-generation 
cephalosporin [37].
The overall clinical success rate in the NIS-FOM study is 
the highest compared to other more recent studies on IV fos-
fomycin with similar design. Dinh et al. reported a favorable 
overall outcome in 76.8% of evaluable patients; BJI 82.6%, 
lung infection 67.7%, UTI 100%, endocarditis or neurologi-
cal infection 83.3%, and bacteremia 57.1% [38]. According 
to Pontikis et al., clinical outcome at day 14 was successful 
in 54.2% of patients, whilst failure, indeterminate outcome 
and superinfection were documented in 33.3%, 6.3% and 
6.3%, respectively [39]. However, in both studies the pro-
portion of MDR pathogens was significantly higher, ranging 
between 70 and 100%. In NIS-FOM, clinical success rates 
ranged from 67% in patients with endocarditis to 89% in 
patients with CNS infection, emphasizing the role of fos-
fomycin in the treatment of GP pathogens [6]. Of note, all 
Table 10  Overview of adverse events
AE adverse event; ITT intention-to-treat population
AE nrelated (% (ITT)) nnot related (% (ITT))
Hypernatremia 22 (10.5%) 9 (4.3%)
Hypokalemia 5 (2.4%) 8 (3.8%)
Diarrhea 3 (1.4%)
Nausea 2 (1%)
Transaminases increased 1 (0.5%)
Pyrexia 1 (0.5%)
Allergic reaction 1 (0.5%)
Hyponatremia 1 (0.5%)
Hyperkalemia 1 (0.5%)
Not specified 1 (0.5%)
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patients with endocarditis developed a bacteremia or sepsis 
concomitantly, hampering a favorable clinical outcome [40]. 
In the subgroup of infections with MDR pathogen (including 
MRSA), clinical and microbiological success was adequate 
(Table 7). The reason for comparatively low clinical and 
microbiological success in patients with intraabdominal 
infections is unknown so far and needs further investigation.
Critically ill patients with impaired organ function and 
intensive co-medication challenge a safe and effective anti-
biotic treatment [42]. Pharmacokinetic interactions are 
common, possibly leading to discontinuation of therapy 
[43]. Many antibiotics, e.g., glycopeptides or colistin, are 
associated with serious adverse events such as nephrotox-
icity, limiting their therapeutic use [44, 45]. However, our 
data show that IV fosfomycin was used in a large dosing 
range. Reported adverse events were generally non-serious 
and expected, without troubling drug/drug interactions. 
Moreover, safety results from the NIS-FOM are in line 
with recent reviews corroborating the good safety profile 
of the substance [6, 15]. Given the sodium load of IV fos-
fomycin, discontinuation of the drug due to accumulating 
high sodium levels in six cases was reasonable to prevent 
potentially serious electrolyte imbalances. One limitation 
of our study is the lack of a control group. Thus, it remains 
unclear how many patients would have developed hyper-
natremia or hypokalemia independent of fosfomycin treat-
ment. In general, hypokalemia is a common problem in ICU 
patients and medication is merely one possible explanation 
[41]. Therefore, clinicians should be aware of disturbances 
in sodium and potassium homeostasis and initiate adequate 
measures early to avoid further complications. Altogether, 
fosfomycin’s safety profile appears advantageous, since the 
generally non-serious and expected nature of adverse events 
constitutes no limiting factor in therapy.
Conclusion
These results suggest that IV fosfomycin is an effective and 
safe combination partner in the treatment of critically ill 
patients with severe infections due to Gram-negative and 
Gram-positive pathogens, even in first-line treatment. Fos-
fomycin was used across different indications and sites of 
infection, independently of the pathogen’s resistance pattern. 
On the other hand, IV fosfomycin is also suitable for highly 
specific patients and settings, when standard treatment might 
be inadequate due to clinical circumstances or has already 
failed. Thus, considering the critical medical condition of 
the study population and the severity of underlying infec-
tions, the high overall success rate of 81% together with an 
advantageous safety profile is very promising and might give 
rise for further prospective clinical trials.
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